(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...

(MENAFN- GlobeNewsWire - Nasdaq) The dynamics of the primary biliary cholangitis market are anticipated to change during the forecast period owing to the rising prevalence of PBC, robust pipeline with ...

SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree and aid monitoring of patients with primary sclerosing cholangitis, according to ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

- Designation based on positive interim analysis of Phase 2b VANTAGE study "Breakthrough Therapy Designation for volixibat in PBC underscores the importance and urgency for a treatment to address one ...

Please provide your email address to receive an email when new articles are posted on . In line with an earlier panel decision, FDA denied full approval to Ocaliva for primary biliary cholangitis. FDA ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily ...